Merck's Q3 results present a mixed outlook. While there are positive indicators such as growth in key products and ongoing cost-cutting measures, the lowered revenue guidance and vaccine supply delays are likely to dampen investor sentiment in the short term. These factors are expected to exert downward pressure on the stock over the next couple of weeks.

[-1]